Benzinga | Jun 28, 2021 06:05AM EDT

Needham Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $85

Needham analyst Joseph Stringer maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and raises the price target from $65 to $85.